Item 5.02. Departure of Directors or Certain Officers; Election of Directors;


           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers.


As previously disclosed, on June 2, 2021, N. Anthony Coles transitioned to the
role of non-executive Chair of the Board of Directors of Yumanity Therapeutics,
Inc. (the "Company").

Item 5.07. Submission of Matters to a Vote of Security Holders




On June 2, 2021, the Company held its previously announced 2021 Annual Meeting
of Stockholders (the "Annual Meeting"), at which a quorum was present. The
proposals voted on at the Annual Meeting and the final voting results for each
proposal are as follows:

1. The Company's stockholders elected the three director nominees listed below to serve as Class III directors until the Company's 2024 annual meeting of stockholders, with the votes cast as follows:





Director Nominee                    Votes For        Votes Against        Abstentions        Broker Non-Votes
N. Anthony Coles, M.D.               4,782,090            1,367,114              4,793               1,350,457
Kim C. Drapkin                       5,972,135              176,601              5,261               1,350,457
Lynne Zydowsky, Ph.D.                6,130,110               18,630              5,257               1,350,457

2. The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021, with the votes cast as follows:





              Votes For   Votes Against   Abstentions   Broker Non-Votes
              7,481,347      12,310         10,797             0

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses